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Abstract
Background: Central serous chorioretinopathy (CSC) is a chorioretinal disease character-
ized by fluid accumulation between the neuroretina and retinal pigment epithelium with 
unknown etiology. Family studies have suggested a heritable component for CSC with an 
autosomal dominant inheritance pattern. Therefore, exome sequencing was performed on 
familial cCSC to indentify the genetic components contributing to familial cCSC.
Methods: Exome sequencing was performed on 72 individuals of 18 families with CSC. In 
these families, we determined whether rare genetic variants (minor allele frequency < 1%) 
were segregated with CSC and also performed familial gene‐burden analysis.
Results: In total, 11 variants segregated in two out of 18 families. One of these vari-
ants, c.4145C>T; p.T1382I (rs61758735) in the PTPRB gene, was also associated 
with CSC in a large case–control cohort sequenced previously (p = 0.009). 
Additionally, in 28 genes two or more different heterozygous variants segregated in 
two or more families, but no gene showed consistent associations in both the family 
gene‐burden results and gene‐burden analysis in the case–control cohort.
Conclusion: We identified potential candidate genes for familial CSC and managed 
to exclude Mendelian inheritance of variants in one or a limited number of genes. 
Instead, familial CSC may be a heterogeneous Mendelian disease caused by variants 
in many different genes, or alternatively CSC may represent a complex disease to 
which both environmental factors and genetics contribute.
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1 |  INTRODUCTION
In central serous chorioretinopathy (CSC), choroidal con-
gestion, thickening, and hyperpermeability have been 
suggested to cause leakage through the retinal pigment ep-
ithelium (RPE). Subsequently, a neuroretinal detachment 
occurs due to the accumulation of serous subretinal fluid 
(Daruich et al., 2015; Gemenetzi, De Salvo, & Lotery, 2010; 
Liew, Quin, Gillies, & Fraser‐Bell, 2013; Warrow, Hoang, 
& Freund, 2013; Yannuzzi, 2010). The exact etiology of 
CSC is still unclear, but male gender and administration of 
exogenous corticoids have been described to be the most 
pronounced risk factors for CSC (Carvalho‐Recchia et al., 
2002; Haimovici, Koh, Gagnon, Lehrfeld, & Wellik, 2004; 
Jonas & Kamppeter, 2005). Other risk factors include en-
dogenous hypercortisolism, stress, and pregnancy (Daruich 
et al., 2015; van Dijk et al., 2016; Liew et al., 2013). 
Moreover, genetic variants that confer risk or are protective 
for CSC have been identified by genetic association studies 
in case–control cohorts (de Jong et al., 2015; Miki et al., 
2014; Moschos et al., 2016; Schellevis et al., 2018; Schubert 
et al., 2014; van Dijk, Schellevis, Bergen et al., 2017).
Although familial occurrence of CSC appears to be rare, 
several reports on familial CSC and the occurrence of CSC 
in multiple generations within a single family have been 
published, pointing to a potential role for genetic factors 
in familial CSC (Lin, Arrigg, & Kim, 2000; Oosterhuis, 
1996; van Dijk, Schellevis, Breukink et al., 2017; Weenink, 
Borsje, & Oosterhuis, 2001). A Mendelian inheritance of 
CSC has been proposed previously based on observations 
that at least two family members proved to have finding 
characteristics for CSC in 52% of 27 families (Weenink et 
al., 2001). Moreover, the presence of affected individuals 
in multiple generations has been described, suggesting an 
autosomal dominant mode of inheritance of familial CSC 
(van Dijk, Schellevis, Breukink et al., 2017). Additionally, 
in 50% of eyes from screened family members of CSC pa-
tients, a thickened choroid (pachychoroid) of more than 
395 µm was detected, which has been described to be the 
underlying choroidal abnormality in various diseases that 
are part of the pachychoroid spectrum (Lehmann, Bousquet, 
Beydoun, & Behar‐Cohen, 2015). However, thus far no ge-
netic studies on familial CSC have been conducted.
Whole‐exome sequencing has proven to be a powerful tool 
to identify novel disease‐associated genes and gene variants 
in many disorders (Gilissen et al., 2010; Gilissen, Hoischen, 
Brunner, & Veltman, 2012). Exons are presumed to harbor about 
85% of disease‐causing mutations, making them a primary target 
to search for disease‐associated variants in CSC families (Choi et 
al., 2009). Therefore, we performed exome sequencing on 72 in-
dividuals of 18 families in which multiple members were found 
to have CSC, in order to determine whether Mendelian inheri-
tance of rare genetic variants causes familial CSC.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
Written informed consent for the enrollment was obtained 
from all subjects. The study adhered to the tenets of the 
Declaration of Helsinki. Approval of the institutional review 
boards and the ethics committees was obtained for all centers 
involved.
2.2 | Subject selection
In this multicenter study, 72 subjects from 18 families, 
including patients with CSC and unaffected family mem-
bers, visited either the Department of Ophthalmology of 
the Radboud University Medical Center ([Radboudumc] 
Nijmegen, the Netherlands) or the Leiden University 
Medical Center ([LUMC] Leiden, the Netherlands). 
Participants were recruited at the outpatient clinic of the 
participating hospitals, after the proband had reported a 
family history of CSC. The majority of the individuals was 
included in our previously published study on the pheno-
typic characteristics of familial CSC and was divided in 
the following groups: “Affected with CSC,” “Suggestive of 
CSC,” or “Unaffected,” using the criteria described before 
(van Dijk, Schellevis, Breukink et al., 2017).
Briefly, subjects were categorized as having CSC when 
serous fluid was detected on an optical coherence tomogra-
phy scan and when one or more “hot spots” of leakage or dif-
fuse leakage was present in combination with irregular RPE 
window defects on fluorescein angiography. Patients were 
excluded if signs of either polypoidal choroidal vasculop-
athy or age‐related macular degeneration (AMD), or other 
atypical findings were present. Suggestive CSC was charac-
terized by RPE alterations typical for CSC, but without the 
presence of either subretinal fluid or 'hot spots' of leakage on 
fluorescein angiography (van Dijk, Schellevis, Breukink et 
al., 2017). Unaffected individuals showed no abnormalities 
on any of the modalities using multimodal imaging.
2.3 | Exome sequencing
Library preparation of the 52 family members of 12 families 
collected at the Radboudumc, Nijmegen was performed with 
the SureSelectXT target enrichment system for Illumina paired‐
end multiplex sequencing according to manufacturer's in-
structions (Version B4, August 2015, Agilent Technologies). 
Completed libraries were sent to the Department of Genetics 
of Maastricht University Medical Center+, Maastricht, the 
Netherlands, where sequencing was performed with eight 
samples per lane using an Illumina HiSeq2000 with 2*100 bp 
chemistry, together with a large cohort of 269 sporadic CSC 
patients (Schellevis et al., 2018 submitted).
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The 20 samples of the six families collected at Leiden 
University Medical Center, Leiden, the Netherlands were 
sent to GenomeScan BV, Leiden, for sequencing. For these 
samples, the Agilent SureSelect V5 enrichment kit was used 
and sequencing was performed with 2*125 bp chemistry on 
the HiSeq2500.
2.4 | Variant calling and recalibration
Data of all individuals were processed according to the 
Genome‐Analysis‐Toolkit (GATK) best practices (v3.8) 
together with the case–control cohort consisting of 269 
sporadic cCSC patients and 1,586 population controls 
(Schellevis et al., 2018 submitted) to improve variant call-
ing. Briefly, BAM to FastQC extraction was performed 
with Picard‐tools (v 1.90), duplicate reads were marked 
with Picard‐tools, and reads were aligned to the reference 
genome (GRCh37.p5 with alternate haplotypes excluded) 
using BWA‐MEM (version v.0.7.12), as described before 
(Schellevis et al., 2018 submitted). Base recalibration was 
performed and subsequent variant calling was performed 
with the HaplotypeCaller algorithm. All GVCFs were 
merged together, and joint genotyping was performed on 
the entire dataset.
Variant recalibration was performed on the entire data-
set with GATK using the recommended settings (McKenna 
et al., 2010), as described before. Genetic variants lo-
cated in low complexity regions of the genome were re-
moved (Li, 2014). Multiallelic variants were extracted with 
VCFtools (v0.1.13) and split using the splitMultiallelic and 
LeftAlignandTrimVariants option in GATK (v3.8). Variants 
with a Hardy–Weinberg equilibrium p < 1 × 10−8 were ex-
cluded. Variants from the adult‐onset genes captured in the 
American College of Medical Genetics and Genomics recom-
mendations for incidental findings (BRCA1 [OMIM:113705], 
BRCA2 [OMIM:600185], MLH1 [OMIM:120436], 
MSH2 [OMIM:609309], MSH6 [OMIM:600678], PMS2 
[OMIM:600259], MUTYH [OMIM:604933]) were removed 
to reduce the risk of secondary findings (Green et al., 2013; 
Kalia et al., 2017). Finally, family members were extracted 
from the dataset and only variants with a minor allele count 
≥1 in the combined family file were retained. Data were an-
notated with Tabanno (https://github.com/zhanxw/anno) and 
Annovar (Yang & Wang, 2015).
2.5 | Variant filtering
Variants were filtered based on a minor allele fre-
quency (MAF) of ≤1% or ≥99% in the following popu-
lations: 1000Genomes_all, 1000Genomes_European, 
Exac_All, Exac_NFE, Exac_FIN, and esp6500siv2_all. 
Additionally, variants with MAF ≥1% in the 1586 controls 
of the sporadic CSC case–control cohort were removed. 
Variants that were annotated by Annovar to be present in 
the exonic or splice site regions were retained and syn-
onymous variants were excluded. Remaining variants 
included: frameshift insertions and deletions (INDELs), 
nonframeshift INDELs, nonsynonymous variants, stop 
gain or loss variants, and variants with unknown effects. 
All variants present in one or more unaffected individuals 
in any of the families were removed assuming complete 
penetrance, with the exception of the unaffected individ-
ual of Family 14, because based on the pedigree structure 
(Figure S1) reduced penetrance appeared to be present in 
this family. Only variants with a CADD score above 20, 
corresponding to the 1% most deleterious variants of the 
human genome, or with an unknown CADD score in case 
of INDELs, were retained.
Next, for each family segregation analysis of variants was 
performed, where variants were retained if they were present 
in all affected individuals of the family and not present in 
unaffected individuals. No filtering was performed for indi-
viduals with suggestive CSC. Variants that segregated in two 
or more families or genes that contained multiple variants 
that segregated in two or more families were retained for 
further evaluation. Familial gene‐burden associations were 
calculated with RareIBD for those genes that carried multi-
ple segregating variants in two or more families (Sul et al., 
2016). The region encompassing the c.4145C>T; p.T1382I 
(rs61758735) variant in the PTPRB [OMIM:176882] gene 
was amplified in additional family members of Family 1 
using AmpliTaq DNA polymerase with the following PCR 
program: 5 min at 95°C, 10 cycles of touchdown starting 
at 62°C for 45 s and lowering the annealing temperature 
0.5°C each cycle, followed by 25 cycles of an annealing 
temperature of 57°C, all these cycles started with 30 s. at 
95°C and ended 45 s at 72°C. The PCR was completed at 
5 min, 72°C and the following primers were used forward 
primer: AGCCTTTGAGCAGCTTTTTC and reverse primer: 
TGATGCTAGTGCCCCATAAG. The PCR product was an-
alyzed by Sanger sequencing at the core sequencing facility 
at the Department of Human Genetics of the Radboudumc.
3 |  RESULTS
In this exome sequencing study on familial CSC, we included 
72 individuals of 18 different families. Out of these 72 indi-
viduals, 33 subjects were affected with CSC, 18 had charac-
teristics suggestive of CSC, and 21 were unaffected (Table 1; 
Figure 1 and Figure S1 for pedigrees). After variant filtering 
based on MAF (≤1%), CADD score (≥20), absence in un-
affected individuals, and protein‐altering effect (frameshift 
INDELs, nonframeshift INDELs, nonsynonymous, stop 
gain/loss variants, and variants with unknown effects), the 
dataset contained 2,806 variants present in 2,368 genes.
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Segregation analysis was performed for all 18 families, 
retaining only variants that were present in the affected in-
dividuals and absent in unaffected individuals. The average 
number of segregating variants in each family was 44 and 
ranged from three to 124 (Table 1). In four families, two 
segregating heterozygous rare variants in the same gene 
were observed. Family 12 carried two variants in KCNMA1 
[OMIM:600150], Family 7 in RBPJL [OMIM:616104], 
Family 8 in SLC26A10 [OMIM:NA], and Family 1 in SP9 
[OMIM:NA] (Table S1). The entire list of segregating vari-
ants for each family is available in Table S2.
Variants that segregated in two or more families were re-
tained for further evaluation. In total, 11 rare variants were 
found to segregate in two families, of which one variant in 
the PTPRB gene was homozygous in one individual, while 
the remaining variants in the SETD2 [OMIM:612778], 
T A B L E  1  Overview of families analyzed for segregating rare variants using exome sequencing
Family
No. of affected 
individuals
No. of suggestive 
individuals
No. of unaffected 
individuals
No. of segregating 
variants
Family 1 2 3 – 75
Family 2 2 – – 69
Family 3 1 3 2 36
Family 4 1 1 4 14
Family 5 1 2 4 3
Family 6 2 2 1 37
Family 7 1 2 3 17
Family 8 3 – 1 17
Family 9 2 – 2 12
Family 10 2 1 – 58
Family 11 2 1 – 79
Family 12 3 – – 29
Family 13 2 – – 71
Family 14a 2 – 1 37
Family 15 2 – – 60
Family 16 2 1 1 21
Family 17 1 1 – 124
Family 18 2 1 2 29
aPossibly reduced penetrance in this family. 
F I G U R E  1  Segregation analysis of 
c.4145C>T; p.T1382I (rs61758735) in the 
PTPRB gene in Family 1 (a) and Family 2 
(b). Genotypes for c.4145C>T; p.T1382I 
(rs61758735) are depicted below each 
individual in the pedigree. Individuals who 
were analyzed by exome sequencing are 
indicated with a blue arrow, while other 
individuals for whom DNA was available 
were analyzed by Sanger sequencing. 
Individual II:2 of family 2 refused to 
participate in the study, and therefore could 
not be analyzed
   | 5 of 11SCHELLEVIS Et aL.
PWP1 [OMIM:NA], ABCA9 [OMIM:612507], 
AT2B2 [OMIM:NA], ZFAND4 [OMIM:NA], MROH5 
[OMIM:NA], ZAN [OMIM:602372], SHISA6 
[OMIM:617327], DCP1A [OMIM:607010], and PPM1E 
[OMIM:NA] genes were heterozygous (Table 2). The ex-
pression of these genes in the retina and RPE was evalu-
ated using the Eye Integration Database. All genes were 
expressed in retina and RPE, except for ZAN (Figure S2) 
(Bryan et al., 2018). The single variant association results 
of these variants were extracted from the sporadic CSC 
case–control dataset (Schellevis et al., 2018 submitted). 
Notably, the variant in the PTPRB gene (c.4145C>T; 
p.T1382I, rs61758735) was significantly associated 
with CSC in the case–control cohort (p = 0.009, Odds 
Ratio = 2.83, 95% Confidence Interval = 1.34–5.97). 
Extended segregation analysis of the PTPRB variant in 
additional available family members of Family 1 revealed 
that two individuals carried the variant homozygously 
(one individual is an affected subject and one is a subject 
with findings suggestive of CSC), six individuals carried 
the variant heterozygously (two affected individuals, two 
individuals with findings suggestive of CSC, and two un-
affected individuals), and one individual did not carry the 
variant (this individual had characteristics suggestive of 
CSC) (Figure 1a). Since two unaffected individuals (of 
which one individual was 74 years old at examination) 
carried the variant heterozygously, complete segregation 
of this variant with the disease in this family was not ob-
served. For Family 2, no additional individuals were avail-
able for extended segregation analysis (Figure 1b).
As a next step, genes that contained multiple variants 
segregating in two or more families were evaluated. In 
28 genes, we observed two or more different heterozy-
gous variants that segregated in two or more families, in-
cluding in two genes known to cause a retinal phenotype 
(ABCA4 [OMIM:601691] and VCAN [OMIM:118661]; 
full list of variants in Table 3). The expression of these 
genes in the retina and RPE was evaluated using the Eye 
Integration Database. All genes, with the exception of 
AGXT [OMIM:604285], LOXHD1 [OMIM:613072], and 
RBPJL, showed moderate to high expression in the RPE 
or retina (Figure S3) (Bryan et al., 2018). For all 28 genes, 
the results of the gene‐based analysis (Burden, SKAT, and 
SKAT‐O) were extracted from the case–control analysis 
(Schellevis et al., 2018 submitted). Also, a family gene‐
burden analysis was performed with RareIBD including 
all rare variants found in all families in the 28 genes. 
Several genes were nominally associated with CSC, but 
no significant associations were observed in either of 
the tests after correction for multiple testing of 28 genes 
(Table 4). Additionally, no genes showed consistent as-
sociations in both the case–control cohort and the family 
cohort. TA
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In this exome sequencing study on familial CSC, we in-
cluded 72 individuals of 18 different families and focused 
on rare genetic variants that segregated with the disease in 
these families. We observed 11 variants that segregated in 
two families, of which one was also associated with CSC in a 
recent case–control study (Schellevis et al., 2018 submitted). 
In addition, in 28 genes two different variants were found to 
segregate in two families, and 25 of these genes showed ex-
pression in the retina or RPE according to the Eye Integration 
Database.
For AMD, a well‐studied multifactorial eye disease with 
phenotypic overlap with CSC, exome sequencing studies in 
families have been successful in identifying rare variants that 
fully or partially segregate with the disease (Geerlings et al., 
2017; Hoffman et al., 2014; Pras et al., 2015; Saksens et al., 
2016; Wagner et al., 2016; Yu et al., 2014). Most variants in 
these AMD families were identified in genes of the comple-
ment system, in which common and rare variants were previ-
ously identified to be associated with AMD in case–control 
cohorts (Fritsche et al., 2016). So far, the only genetic as-
sociation that has been consistently been replicated in CSC 
was identified for common variants in the complement factor 
H (CFH [OMIM:134370]) gene (de Jong et al., 2015; Miki 
et al., 2014; Moschos et al., 2016; Schellevis et al., 2018). 
However, in this study, we did not observe any segregating 
rare variants in CFH in CSC families.
In this first unbiased exome sequencing study in a large 
cohort of families with CSC, we did not identify either a sin-
gle variant or multiple variants in a single gene that segre-
gated with the CSC phenotype. This excludes that familial 
CSC is a Mendelian disease caused by mutations in a single 
gene. Analysis of exome sequencing data identified numer-
ous variants that segregate with the disease in each individual 
family. However, with this study setting, it is impossible to 
identify which of these variants might have an effect on the 
phenotype. Therefore, we focused on variants that segregated 
with CSC in at least two families, and on genes that carried 
multiple variants that segregated with CSC in at least two 
families.
In total, 11 segregating variants were observed in two 
families, of which the c.4145C>T; p.T1382I (rs61758735) 
variant in the PTPRB gene showed an association in the 
sporadic CSC case–control cohort (Schellevis et al., 2018 
submitted). However, extended segregation analysis in addi-
tional family members excluded complete segregation of the 
PTPRB variant with the disease in one of two families. This 
is in line with results obtained in AMD families, in which 
rare variants did not always completely segregate with 
the disease (Duvvari et al., 2016; Geerlings et al., 2017; 
Hoffman et al., 2014; Saksens et al., 2016). Nevertheless, 
these variants are likely to contribute to the disease in these 
families, since several rare variants that are significantly 
associated with AMD in case–control studies often also 
show partial segregation in families (Geerlings et al., 2017; 
Saksens et al., 2016).
The PTPRB gene encodes the vascular endothelial 
protein tyrosine phosphatase (VEPTP) protein. Vascular 
endothelial protein tyrosine phosphatase is an important 
modulator of vascular endothelium morphogenesis and is 
involved in promoting angiogenesis and in regulating en-
dothelial barrier functions by interacting with cadherin 
(Baumer et al., 2006; Nottebaum et al., 2008). Furthermore, 
intra‐ocular injections of anti‐VEPTP have been found to 
T A B L E  4  Gene‐based analysis results of the genes with multiple 
segregating variants in two or more families
Gene
Case–control analysisa Family analysis
Burden SKAT SKAT‐O RareIBD
ABCA4 0.074 0.295 0.129 0.051
ABCF3 0.386 1.000 0.523 0.047
AGXT 0.374 0.367 0.517 0.301
ARFGEF3 0.126 0.166 0.198 0.085
BAIAP3 0.076 0.663 0.132 0.143
COL22A1 0.564 0.506 0.684 0.020
CSMD2 0.460 0.266 0.471 0.328
DPH1 0.039 0.220 0.061 0.086
KIAA1324 0.074 0.035 0.051 0.097
KIF13B 0.053 0.026 0.044 0.288
KRIT1 0.345 0.821 0.446 0.021
LOXHD1 0.567 0.960 0.761 0.049
LTBP2 0.378 0.827 0.553 0.177
MARF1 0.710 1.000 0.878 0.094
MYH2 0.858 0.452 0.655 0.037
MYOF 0.016 0.128 0.025 0.144
NOTCH4 0.544 0.939 0.740 0.018
PREX1 0.044 0.165 0.073 0.061
RBPJL 0.131 0.262 0.195 0.014
RECQL4 0.234 0.538 0.391 0.144
RFT1 0.073 0.341 0.130 0.019
SETX 0.587 0.494 0.667 0.169
TCF25 0.782 0.594 0.829 0.191
TTN 0.577 0.435 0.596 0.072
USP20 0.226 0.948 0.354 0.215
VCAN 0.271 1.000 0.414 0.144
YLPM1 0.524 0.871 0.715 0.047
ZPLD1 0.237 1.000 0.373 0.110
ap‐values lower than 0.05 are indicated in bold; Burden, SKAT, and SKAT‐O 
results were obtained from a recent case–control study performed with 263 spo-
radic CSC patients and 1,352 population controls (Schellevis et al., 2018 
submitted). 
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suppress neovascularization in mice (Shen et al., 2014). As 
it has been hypothesized that choroidal hyperpermeability 
and dysfunction is the most important underlying problem 
in CSC (Daruich et al., 2015), the PTPRB gene is an in-
teresting candidate gene for CSC and should be investi-
gated in future studies. Variants in the PTPRB gene could 
potentially predispose individuals to an impaired vascular 
network resulting in and leakage and occurrence of CSC. 
The remaining 11 variants were very rare or even absent 
in the case–control cohort, and we can neither rule out nor 
confirm their possible role in the CSC disease mechanism 
at this time.
In 28 genes, multiple different segregating variants 
were observed in at least two families. For these genes, 
gene‐based associations in the case–control cohort (using 
SKAT, SKAT‐O, and Burden test) and gene‐based associa-
tions in the CSC families (using RareIBD) were evaluated. 
Five genes were nominally associated in the gene‐burden 
analyses of the case–control cohort and nine genes were 
nominally associated in the family dataset. However, none 
of the genes showed consistent associations in both the 
gene‐burden analysis in the case–control cohort and in 
the family gene‐burden analysis. Of the five genes nom-
inally associated in the case–control cohort, the DPH1 
[OMIM:603527], KIAA1324 [OMIM:611298], and PREX1 
[OMIM:606905] genes showed a trend toward association 
in the family dataset and might be interesting genes for 
replication in a larger CSC cohorts.
In summary, we aimed to identify rare variants associated 
with familial CSC. In each family, many variants segregated 
with the disease, but only few were found to segregate in at 
least two families. One of these variants was also associated 
with CSC in a recent case–control cohort (Schellevis et al., 
2018 submitted), and this gene, PTPRB, has a function that 
could be of importance in the etiology of CSC. Therefore, 
PTPRB might be an interesting candidate gene for future 
studies on CSC. Future analyses should include additional 
families with more individuals to increase the chance of find-
ing segregating variants in multiple families, and to increase 
the power of the RareIBD analysis. However, this may be 
challenging due to the relatively rare occurrence of familial 
CSC. Additionally, future studies may focus on the potential 
role of genetic variants in noncoding genetic regions, such as 
introns and promoter regions or large structural alterations 
that cannot be detected with exome sequencing, such as copy 
number variations.
In general, in familial CSC, a Mendelian inheritance pat-
tern of variants in one or a limited number of genes can be 
excluded based on this study. Instead, familial CSC may be a 
heterogeneous Mendelian disease caused by variants in many 
different genes, or alternatively CSC may represent a com-
plex disease to which both genetic and environmental factors 
contribute.
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